Recombinant Human WT1 Protein, His-tagged

• Cat.No.: WT1-626H
• Product Overview: Recombinant Human WT1,transcript variant B, fused with His tag at N-terminal was expressed in E. coli.

Specification

• Description: This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described. In several variants, there is evidence for the use of a non-AUG (CUG) translation initiation codon upstream of, and in-frame with the first AUG. Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated.
• Source: E. coli
• Species: Human
• Tag: His
• Form: 25mM Tris, pH8.0, 150 mM NaCl, 10% glycerol, 1 % Sarkosyl.
• Molecular Mass: 55.8 kDa
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining
• Concentration: >50 ug/mL as determined by microplate BCA method

Gene Information

• Gene Name: WT1 Wilms tumor 1 [ Homo sapiens ]
• Official Symbol: WT1
• Synonyms: WT1; Wilms tumor 1; GUD; Wilms tumor protein; AWT1; WAGR; WIT 2; amino-terminal domain of EWS|last three zinc fingers of the DNA-binding domain of WT1; WT33; NPHS4; WIT-2; EWS-WT1
• Gene ID: 7490
• mRNA Refseq: NM_000378
• Protein Refseq: NP_000369
• MIM: 607102
• UniProt ID: P19544

Reviews

10/10/2020

It has been widely employed in protein electron microscopy structure analysis, where it has demonstrated remarkable efficacy.

10/25/2019

Broad applicability make it a valuable asset for a wide range of research endeavors.

05/07/2017

Researchers can rely on the WT1 Protein to deliver reliable and reproducible results, facilitating robust data interpretation and scientific advancements.

Q&As

What therapeutic strategies are being explored for cancers with abnormal WT1 expression?

Targeted therapies and immunotherapies aimed at inhibiting or modulating WT1 expression are being investigated for their potential in cancer treatment.

In what other cancers is the WT1 protein targeted for diagnostic purposes?

Apart from Wilms' tumor, WT1 is examined in leukemia, mesothelioma, and some solid tumors as a diagnostic marker.

Can WT1 be a target for personalized cancer therapy?

Yes, understanding the WT1 status in a patient's cancer can guide the development of personalized treatment plans, potentially improving outcomes.

Are there any ongoing clinical trials focused on the WT1 protein and cancer?

Yes, there are several clinical trials exploring the role of WT1 as a therapeutic target and its potential in cancer treatment.

How does the WT1 protein contribute to the prognosis of cancer patients?

High levels of WT1 expression are often associated with poor prognosis in various cancers, indicating a more aggressive disease course.